Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes

BACKGROUND: The authors evaluated mocetinostat (a class I/IV histone deacetylase inhibitor) in patients with urothelial carcinoma harboring inactivating mutations or deletions in CREB binding protein [CREBBP] and/or E1A binding protein p300 [EP300] histone acetyltransferase genes in a single‐arm, op...

Descripción completa

Detalles Bibliográficos
Autores principales: Grivas, Petros, Mortazavi, Amir, Picus, Joel, Hahn, Noah M., Milowsky, Matthew I., Hart, Lowell L., Alva, Ajjai, Bellmunt, Joaquim, Pal, Sumanta K., Bambury, Richard M., O’Donnell, Peter H., Gupta, Sumati, Guancial, Elizabeth A., Sonpavde, Guru P., Faltaos, Demiana, Potvin, Diane, Christensen, James G., Chao, Richard C., Rosenberg, Jonathan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590473/
https://www.ncbi.nlm.nih.gov/pubmed/30570744
http://dx.doi.org/10.1002/cncr.31817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590473/
https://www.ncbi.nlm.nih.gov/pubmed/30570744
http://dx.doi.org/10.1002/cncr.31817

Ejemplares similares